TNFAIP3 and ductal breast carcinoma in situ: Interestingly, AP20187 treatment also upregulated TNFAIP3 protein in two DCIS-iFGFR1 cell lines with ERK1 KO as it did in DCIS-iFGFR1 control cells with wild-type ERK1/2.